Hyperactive Delirium Requires More Aggressive Management in Patients with COVID-19: Temporarily Rethinking "Low and Slow".
Clicks: 217
ID: 106945
2020
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.3
/100
11 views
11 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Delirium is a common symptom in patients admitted to our hospital with COVID-19, and in cases of hyperactive delirium we have frequently observed behaviors that pose a significant risk of disease transmission to health care providers. Managing this symptom has emerged as an important challenge, as our local health care system has been strained by providers becoming sick or quarantined. Preventative and non-pharmacologic interventions remain critical for managing delirium in such patients, though occasionally pharmacologic treatment is required. When use of an antipsychotic medication is indicated, we recommend that providers consider foregoing the lowest common dose and instead start with the next incrementally higher dose to more quickly and reliably ensure the safety of both patients and providers. We do not recommend initiating prophylactic treatment or escalating doses in a manner that conflicts with currently accepted guidelines without carefully considering the risks and benefits.
| Reference Key |
sanders2020hyperactivejournal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sanders, Barton J;Bakar, Melissa;Mehta, Sonal;Reid, M Carrington;Siegler, Eugenia L;Abrams, Robert C;Adelman, Ronald D;Lachs, Mark S; |
| Journal | Journal of pain and symptom management |
| Year | 2020 |
| DOI |
S0885-3924(20)30389-4
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.